Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050661 · ClinicalTrials.gov registry record · Phase 1
To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00050661 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 6 participants.
The verdict
NCT00050661, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse.
Interventions
- DRUG Daclizumab
- DEVICE NB-UVB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 1997-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050661
The ClinicalTrials.gov registry entry for NCT00050661 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Daclizumab is the first listed.
NCT00050661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050661 about?
NCT00050661 is a clinical study titled "To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris". This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse.
What is the current status of trial NCT00050661?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 1997-10. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00050661?
The interventions under investigation include: Daclizumab (DRUG), NB-UVB (DEVICE).
Who is sponsoring clinical trial NCT00050661?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.